Kymera Therapeutics Inc

2026-08-05 20:02; UTC

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

2026-08-04 20:04; UTC

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

2026-08-03 19:46; UTC

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

2026-07-31 20:06; UTC

Kymera shares lower amid SPDR S&P Biotech ETF decline.

2026-07-30 19:39; UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

2026-07-29 19:32; UTC

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

2026-07-28 17:42; UTC

Shares lower despite Guggenheim's price target increase to $135.

2026-07-27 21:03; UTC

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

2026-07-24 18:46; UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

2026-07-21 19:16; UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

2026-07-20 22:16; UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.